Inferra AIResearch Tools

Inferra AI / Company / BSX

Boston Scientific

BSX · Health Care

Last earnings Oct 28, 2026

Key results

GAAP net incomequarter

$755 million

The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieved adjusted 3 EPS of $0.75 for the period, compared to $0.63 a year ago.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Revenuequarter

21.5 percent

Achieved the following net sales growth in each reportable segment, compared to the prior year period MedSurg 16.4 percent reported, 15.6 percent operational and 7.6 percent organic Cardiovascular 22.4 percent reported, 21.5 percent operational and 19.4 percent organic Achieved the following net sales growth (declines) in each region, compared to the prior year period United States (U.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

AI analysis

Q3 2025 · reported Oct 22, 2025

Based on: Earnings release + parent 8-K — transcript not held

GAAP net income · Q3 2025
$755M
EX-99 · Oct 22, 2025
Revenue · Q3 2025
21.5 percent
EX-99 · Oct 22, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
GAAP net income$755 million——
Revenue21.5 percent——

EX-99 · Oct 22, 2025

Guidance · company-stated

sales

“growth for the full year 2025, versus the prior year period, to be approximately 20 percent”

EPS

“on a GAAP basis in a range of $1.97 to $2.01”

adjusted EPS

“, excluding certain charges (credits), of $3.02 to $3.04”

net sales

“growth for the fourth quarter of 2025, versus the prior year period, to be in a range of approximately 14.5 to 16.5 percent”

Guidance stated in the release's Business Outlook table for Full Year; no direction stated — figures as stated in the table.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Boston Scientific Q3 2025 — The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or $0.51 per share (EPS), compared to $469 million or $0.32 per share a year ago, and achieve…

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

sales: “sales growth for the full year 2025, versus the prior year period, to be approximately 20 percent”

EPS: “EPS on a GAAP basis in a range of $1.97 to $2.01”

adjusted EPS: “adjusted EPS, excluding certain charges (credits), of $3.02 to $3.04”

net sales: “net sales growth for the fourth quarter of 2025, versus the prior year period, to be in a range of approximately 14.5 to 16.5 percent”

sales (“Full Year”)
“sales growth for the full year 2025, versus the prior year period, to be approximately 20 percent”

EPS (“Full Year”)
“EPS on a GAAP basis in a range of $1.97 to $2.01”

adjusted EPS (“Full Year”)
“adjusted EPS, excluding certain charges (credits), of $3.02 to $3.04”

net sales (“Full Year”)
“net sales growth for the fourth quarter of 2025, versus the prior year period, to be in a range of approximately 14.5 to 16.5 percent”

Guidance stated in the release's Business Outlook table for Full Year; no direction stated — figures as stated in the table.

Capital allocation

Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Strategy & priorities

As we shared at our recent Investor Day meeting, we are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

These restructuring plans each consist of distinct initiatives that are fundamentally different from our ongoing, core cost reduction initiatives in terms of, among other things, the frequency with which each action is performed and the required planning, resourcing, cost and timing.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Examples of such initiatives include the movement of business activities, facility consolidations and closures and the transfer of product lines between manufacturing facilities, which, due to the highly regulated nature of our industry, requires a significant investment in time and cost to create duplicate manufacturing lines, run product validations and seek regulatory approvals.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

In contrast to our ongoing cost reduction initiatives, restructuring plans typically result in duplicative cost and exit costs over the defined timeframe and are not considered part of our core, ongoing operations.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Risks & headwinds

Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union (EU) Medical Device Regulation (MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Risks and uncertainties that may cause such differences include, among other things economic conditions, including the impact of foreign currency fluctuations future U.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.

SEC original ↗Boston Scientific — Earnings release (8-K exhibit)EX-99Oct 22, 2025

Documents

Earnings deck slides

3 decks with slide view

Boston Scientific — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Slide history — recurring slides by stated title

Slides are matched across this company’s decks by their stated title only; a title listed here appeared in more than one held deck.

Boston Scientific Announces — Oct 28, 2026 · slide 1 · Oct 28, 2026 · slide 1

Safe harbor for forward-looking statements — Oct 28, 2026 · slide 2 · Oct 28, 2026 · slide 2

Transaction Details — Oct 28, 2026 · slide 11 · Oct 28, 2026 · slide 6

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

68 documents

Earnings releases

17 documents

Presentations

4 documents

Transcripts

0 documents

No transcripts for Boston Scientific are held in this edition of the library.

Mentioned by

5 companies

Other tracked companies whose held documents mention Boston Scientific by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.